323 related articles for article (PubMed ID: 36258106)
1. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.
Ng JJ; Ong ST
Curr Hematol Malig Rep; 2022 Dec; 17(6):181-197. PubMed ID: 36258106
[TBL] [Abstract][Full Text] [Related]
2. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.
Al Hamad M
F1000Res; 2021; 10():1288. PubMed ID: 35284066
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
5. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
6. Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S; Fernandes A; Shahrin N; Maqsood M; Shanmuganathan N; Wadham C
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394774
[TBL] [Abstract][Full Text] [Related]
7. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
8. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
Huang R; Kang Q; Liu H; Li Y
Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
[TBL] [Abstract][Full Text] [Related]
10. Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP; Eide CA; Druker BJ
Cancer Cell; 2020 Apr; 37(4):530-542. PubMed ID: 32289275
[TBL] [Abstract][Full Text] [Related]
11. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
12. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
15. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
Gonzalez MA; Olivas IM; Bencomo-Alvarez AE; Rubio AJ; Barreto-Vargas C; Lopez JL; Dang SK; Solecki JP; McCall E; Astudillo G; Velazquez VV; Schenkel K; Reffell K; Perkins M; Nguyen N; Apaflo JN; Alvidrez E; Young JE; Lara JJ; Yan D; Senina A; Ahmann J; Varley KE; Mason CC; Eide CA; Druker BJ; Nurunnabi M; Padilla O; Bajpeyi S; Eiring AM
Clin Transl Med; 2022 Dec; 12(12):e1146. PubMed ID: 36536477
[TBL] [Abstract][Full Text] [Related]
16. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
17. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
Yaghmaie M; Yeung CC
Curr Hematol Malig Rep; 2019 Oct; 14(5):395-404. PubMed ID: 31463864
[TBL] [Abstract][Full Text] [Related]
19. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.
Brumatti G; Kaloni D; Castro FA; Amarante-Mendes GP
Biochem J; 2023 Jan; 480(2):161-176. PubMed ID: 36719792
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
